Paper
Dalton Transactions
which proceed via a CMD, the more electron-rich position is
favoured (by Pd and ultimately by the coupling partner). They
determined that a CMD route, which would give arylation at
the C-3 position, due to the greater π-electron density at that
position, was in contrast to the experimentally observed C-2
arylation. However, when carbopalladation was evoked by Choi
et al., palladation did occur at the most electron-rich site, but
the coupling partner (i.e. aryl group) was delivered to the
2 D. A. Horton, G. T. Bourne and M. L. Smythe, Chem. Rev.,
2003, 103, 893–930.
3 G. P. McGlacken and L. M. Bateman, Chem. Soc. Rev., 2009,
38, 2447–2464.
4 D. J. Constable, P. J. Dunn, J. D. Hayler, G. R. Humphrey,
J. L. Leazer Jr., R. J. Linderman, K. Lorenz, J. Manley,
B. A. Pearlman and A. Wells, Green Chem., 2007, 9, 411–
420.
neighbouring
regioselectivity.
carbon,
resulting
in
the
observed
5 D. L. Davies, S. M. Donald and S. A. Macgregor, J. Am.
Chem. Soc., 2005, 127, 13754–13755.
In contrast to that used by Choi et al., our system does not
possess a suitable destination for the phenyl group, after C-3
palladation. Moreover, the electron donating properties of the
O-tether may play a role. Thus in our case, CMD becomes the
mode of choice in both C–H activation steps, with the cou-
marin C-3–H cleaved first. Finally, our system does not benefit
from the statistical effect of a large excess of the aryl coupling
partner (40-fold vs. 1 equivalent), although it is difficult to
assess this contribution.
6 D. L. Davies, S. M. Donald, O. Al-Duaij, S. A. Macgregor and
M. Pölleth, J. Am. Chem. Soc., 2006, 128, 4210–4211.
7 Y. Boutadla, D. L. Davies, S. A. Macgregor and
A. I. Poblador-Bahamonde, Dalton Trans., 2009, 5820–
5831.
8 D. García-Cuadrado, A. A. C. Braga, F. Maseras and
A. M. Echavarren, J. Am. Chem. Soc., 2006, 128, 1066–1067.
9 D. García-Cuadrado, P. de Mendoza, A. A. Braga, F. Maseras
and A. M. Echavarren, J. Am. Chem. Soc., 2007, 129, 6880–
6886.
1
1
1
1
1
0 M. Lafrance and K. Fagnou, J. Am. Chem. Soc., 2006, 128,
16496–16497.
1 M. Lafrance, C. N. Rowley, T. K. Woo and K. Fagnou, J. Am.
Chem. Soc., 2006, 128, 8754–8756.
2 S. I. Gorelsky, D. Lapointe and K. Fagnou, J. Am. Chem.
Soc., 2008, 130, 10848–10849.
Conclusions
In conclusion, the CDC of 4-phenoxy-2-coumarins is most
likely to proceed via the mechanism shown in Scheme 4. It
comprises of an initial, reversible C–H activation of the C-3–H
bond of the 2-coumarin via CMD, followed by irreversible,
turnover-limiting CMD of the aryl C–H bond. Reductive elimin-
ation of Pd(0) gives the product, and deprotonation and oxi-
dation of the Pd(0) back to the active catalyst Pd(II) completes
the catalytic cycle. The experimental evidence is consistent
with the DFT calculations. This work demonstrates that a
double CMD mechanism is accessible in the absence of suit-
able substrates for carbopalladation and provides key insights
into the C–H activation of coumarins, and the order of C–H
cleavage.
3 D. Lapointe and K. Fagnou, Chem. Lett., 2010, 39, 1118–
1
126.
4 S. I. Gorelsky, D. Lapointe and K. Fagnou, J. Org. Chem.,
012, 77, 658–668.
2
1
1
1
5 S. I. Gorelsky, Organometallics, 2012, 31, 794–797.
6 S. I. Gorelsky, Coord. Chem. Rev., 2013, 257, 153–164.
7 D. L. Davies, S. A. Macgregor and C. L. McMullin, Chem.
Rev., 2017, 117, 8649–8709.
8 H. Choi, M. Min, Q. Peng, D. Kang, R. S. Paton and
S. Hong, Chem. Sci., 2016, 7, 3900–3909.
1
1
2
2
9 C.-J. Li and Z. Li, Pure Appl. Chem., 2006, 78, 935–945.
0 C.-J. Li, Acc. Chem. Res., 2009, 42, 335–344.
1 S. A. Girard, T. Knauber and C.-J. Li, Angew. Chem., Int. Ed.,
Conflicts of interest
2014, 53, 74–100.
There are no conflicts of interest to declare.
2
2 S. A. Girard, T. Knauber and C.-J. Li, in From C-H to C-C
Bonds: Cross-Dehydrogenative-Coupling, The Royal Society of
Chemistry, Cambridge, UK, 2015, pp. 1–32.
Acknowledgements
23 M. Min, Y. Kim and S. Hong, Chem. Commun., 2013, 49,
196–198.
This research was supported by Science Foundation Ireland
2
2
2
4 M. Min and S. Hong, Chem. Commun., 2012, 48, 9613–9615.
5 J. Dickinson, Nat. Prod. Rep., 1993, 10, 71–98.
6 G. P. McGlacken and I. J. S. Fairlamb, Nat. Prod. Rep., 2005,
(
SFI/12/IP/1315 & SFI/12/RC/2275) and the Synthesis and Solid
State Pharmaceutical Centre (SSPC) (G. P. M. and
A. M. P.). A. M. P. and G. P. M wish to thank Dr Davide Tiana
for helpful discussion during the preparation of the
manuscript.
22, 369–385.
27 A. Goel, G. Taneja, A. Raghuvanshi, R. Kant and
P. R. Maulik, Org. Biomol. Chem., 2013, 11, 5239–5253.
28 M. Costa, T. A. Dias, A. Brito and F. Proença, Eur. J. Med.
Chem., 2016, 123, 487–507.
2
Notes and references
9 K. Mackey, L. M. Pardo, A. M. Prendergast, M.-T. Nolan,
L. M. Bateman and G. P. McGlacken, Org. Lett., 2016, 18,
2540–2543.
1
J. Hassan, M. Sévignon, C. Gozzi, E. Schulz and
M. Lemaire, Chem. Rev., 2002, 102, 1359–1470.
Dalton Trans.
This journal is © The Royal Society of Chemistry 2018